GlassScriptPhysician profile
Liza A Rodriguez
NPI 1356591028
$11,499.57
in general payments reported to CMS, 2019-2025
20 companies · $9,867 in 2025
The $9,867 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $79.98 · 2022: $113 · 2023: $594 · 2024: $846 · 2025: $9,867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,945 · Food and Beverage: $2,921 · Travel and Lodging: $2,341 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,945.00 |
| Food and Beverage | $2,921.03 |
| Travel and Lodging | $2,340.70 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $8,853.29 | 2024-2025 | Jakafi, Niktimvo |
| Astellas Pharma US INC | $447.74 | 2021-2025 | Cresemba, Xospata |
| Sanofi-Aventis U.S. LLC | $303.50 | 2025 | |
| Genmab U.S., INC. | $276.42 | 2024-2025 | Epkinly |
| Celgene Corporation | $204.13 | 2024-2025 | Breyanzi, Abecma |
| Abbvie INC. | $176.82 | 2023-2025 | |
| Genzyme Corporation | $133.80 | 2023 | |
| Sobi, INC | $130.66 | 2025 | |
| Pfizer INC. | $126.83 | 2023-2024 | |
| Janssen Biotech, INC. | $118.89 | 2025 | Carvykti, Rybrevant |
| Genentech USA, INC. | $117.85 | 2023 | Polivy, Lunsumio |
| Janssen Scientific Affairs, LLC | $116.79 | 2024 | Talvey, Imbruvica |
| Kite Pharma, INC. | $112.87 | 2022 | |
| Daiichi Sankyo INC. | $99.99 | 2024 | Vanflyta |
| Amgen INC. | $96.39 | 2024 | Imdelltra (Amg 757) |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Btg International INC. | $75.91 | 2024 | |
| Adc Therapeutics America, INC. | $42.00 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $25.95 | 2025 | Lynozyfic |
| Syndax Pharmaceuticals, INC. | $20.21 | 2025 | |
| Taiho Oncology, INC. | $19.53 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liza Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.